hCCR8(2)
모델명
C57BL/6Smoc-Ccr8em3(hCCR8)/Smoc
카탈로그
NM-HU-2000054
모델 상태
Repository Live
유전자 요약
Official Symbol
CCR8
모델 설명
검증 데이터
Fig1. Expression characterization of CCR8 humanized mouse.
(A) Human CCR8 expression on activated splenic CD4+, CD8+ and Treg cells upon anti-mCD3/mCD28 stimulation in hCCR8 mice; (B) Statistics of T cell populations in hCCR8 mice.
Fig2. The anti-hCCR8 therapeutic antibody shows potent antitumor efficacy in hCCR8 mice.
(A) and (B) in vivo antitumor response of anti-hCCR8 in hCCR8 mice bearing MC38 tumor.
Fig3. In vivo antitumor responses of anti-hCCR8 alone or in combination with anti-PD-1 in hCCR8 knockin mice engrafted with MC38 tumor.
(A) Mean tumor growth curves upon treatment; (B) Individual tumor growth curves upon treatment.
Fig4. In vivo efficacy study in CCR8 humanized mice grafted with MC38 tumor model. JTX-1811 can inhibit the growth of MC38 xenografts (A) without significant effect on the body weight of CCR8 humanized mice (B).(provided by partner)
당신은 또한 좋아할 수 있습니다
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
조회At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
조회